Predictive Oncology and Every Cure have announced a strategic collaboration aimed at identifying and prioritizing existing drugs for repurposing to improve cancer patient outcomes. The partnership combines Predictive Oncology's extensive tumor biobank and AI-driven drug discovery platform with Every Cure's artificial intelligence models for drug repurposing.
Leveraging Extensive Tumor Sample Database
The collaboration centers on Predictive Oncology's vast biobank containing more than 150,000 tumor samples across more than 130 different cancer types. "This collaboration on drug repurposing leverages our unique assets and capabilities, most notably our vast biobank of more than 150,000 tumor samples across more than 130 different cancer types," said Raymond F. Vennare, CEO of Predictive Oncology. "Together we believe we can make a meaningful difference in the lives of patients in need, and we are pleased to be able to assist Every Cure in advancing these efforts."
AI-Powered Drug Discovery Platform
Predictive Oncology's scientifically validated AI platform, PEDAL, demonstrates the ability to predict with 92% accuracy if a tumor sample will respond to a certain drug. This capability allows for more informed selection of drug/tumor type combinations for subsequent in-vitro testing. The platform uses machine learning models and AI to predict patient tumor drug response based on wet lab testing that accesses thousands of human tumor samples and associated data housed at Predictive Oncology's CLIA laboratory.
Comprehensive Drug Repurposing Approach
Every Cure's AI models employ knowledge graphs, large language models, and real-world medical data to identify and rank potential connections between existing drugs and diseases. Top-ranked opportunities undergo rigorous evaluation by Every Cure's experienced team, who determine the requirements to bring treatments safely to patients. In some cases, Every Cure generates additional pre-clinical or clinical evidence and engages with research partners, regulators, and patient organizations to maximize patient impact and ensure treatments reach those who need them.
Organizational Capabilities
Predictive Oncology positions itself on the cutting edge of artificial intelligence and machine learning applications in early drug discovery and drug development for cancer patients worldwide. The company's AI-based drug discovery solutions are complemented by its wholly owned CLIA laboratory facility and are headquartered in Pittsburgh, PA.
Every Cure operates as a nonprofit biotech organization committed to unlocking the potential of existing medicines to treat as many diseases as possible. The organization has received recognition as both an Audacious Project grantee from TED and a Founder's Prize recipient from Elevate Prize Foundation, with media coverage including Good Morning America, USA Today, and the Wall Street Journal.
